Drug firm Lupin Friday said the US health regulator has completed inspection of its Nagpur facility in Maharashtra without any observation.
The product specific pre-approval inspection by USFDA concluded without any observation, Lupin said in a BSE filing.
Shares of Lupin were trading at Rs 972.80 apiece, up 1.72 per cent, from the previous close on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
